Aside from the important role of brain natriuretic peptide (BNP) in diagnosis, and differential diagnosis of heart failure, this biological peptide has proved to be an independent surrogate marker of rehospitalization...Aside from the important role of brain natriuretic peptide (BNP) in diagnosis, and differential diagnosis of heart failure, this biological peptide has proved to be an independent surrogate marker of rehospitalization and death of the fatal disease. Several randomized clinical trials demonstrated that drugs such as beta blocker, angiotensin converting enzyme inhibitor, spiro- nolactone and amiodarone have beneficial effects in decreasing circulating BNP level during the management of chronic heart failure. The optimization of clinical decision-making appeals for a representative surrogate marker for heart failure prognosis. The serial point-of-care assessments of BNP concentration provide a therapeutic goal of clinical multi-therapy and an objective guid- ance for optimal treatment of heart failure. Nevertheless new questions and problems in this area remain to be clarified. On the basis of current research advances, this article gives an overview of BNP peptide and its property and role in the management of heart failure.展开更多
Objectives To observe the efficacy and safety of recombinant human brain natriuretic peptide(rh-BNP) on patients with acute myocardial infarction complicating congestive heart failure.Methods 40 patients with acute my...Objectives To observe the efficacy and safety of recombinant human brain natriuretic peptide(rh-BNP) on patients with acute myocardial infarction complicating congestive heart failure.Methods 40 patients with acute myocardial infarction complicated by congestive heart failure were randomly divided into control group and treatment group of 20 cases.The control group,15 cases of acute anterior myocardial infarction,5 cases of acute inferior wall myocardial infarction, 15 males and 5 females,aged 55-70 years,mean age 58±12 years;treated 16 cases of acute anterior myocardial infarction,4 cases of acute myocardial infarction,16 males and 4 females,aged 56-70 years,mean age 59±11 years;two groups of age,gender,severity of disease and vascular lesions no significant difference and comparable(P】0.05).Conventional group were given aspirin,clopidogrel, statins,Inotropic,diuretic and vasodilator therapy.In the con- ventional treatment group based on the use of recombinant human brain natriuretic peptide(new bios,Tibet Pharmaceutical Co.,Ltd.Chengdu Nuodikang biopharmaceutical production, usage:1.5μg/Kg intravenous injection(impact), then 0.0075μg-0.01μg/(kg·min)infusion rate).Continuous medication 72 h.The clinical symptoms observed for 3 days in patients before treatment and after treatment,heart rate,blood pressure and left ventricular ejection fraction (LVEF) and tumor necrosis factor(TNF-α),brain natriuretic peptide(BNP) levels were measured.Results In control group,8 cases markedly effect,5 cases effect and 7 cases no effect,the total effective rate was 65%;In treatment group,13 cases markedly effect,6 cases effect and 1 cases no effect,the total effective rate was 95%,compared with two groups P New bios treatment group significantly increased cardiac index(CI) in patients with heart failure and left ventricular ejection fraction(LVEF) than the control group(all P【0.05),further reduce the levels of tumor necrosis (TNF-α) and brain natriuretic peptide(BNP).Conclusions rh-BNP can improve symptoms and heart function,reduced plasma tumor necrosis factor(TNF-α) and BNP levels of acute myocardial infarction patients with congestive heart failure,the treatment safe and reliable.As small sample size observed,larger sample to be accumulated to further evaluate its efficacy and safety.展开更多
Introduction: The use of repeated thermal therapy for improving the symptoms of chronic heart failure (CHF) has been recently demonstrated. Usually, thermal therapy requires an infrared dry sauna. However, it is diffi...Introduction: The use of repeated thermal therapy for improving the symptoms of chronic heart failure (CHF) has been recently demonstrated. Usually, thermal therapy requires an infrared dry sauna. However, it is difficult for small clinics to acquire such an expensive and extensive system. The author assessed the efficacy of its substitution with hot water bottles. Moreover, there are no prior studies demonstrating the efficacy of thermal therapy in hemodialysis patients with chronic heart failure. Methods: The author evaluated plasma brain natriuretic peptide (BNP) levels in 98 hemodialysis patients in a clinic. A total of nine patients whose BNP levels were more than 500 pg/mL agreed to be enrolled in this study and received thermal therapy using hot water bottles. Results: Plasma BNP levels, a potential marker for CHF, tended to decrease (891 ± 448 pg/mL to 680 ± 339 pg/mL), but the difference was not significant (P = 0.0845). The oral temperature changed from 36.44℃± 0.45℃ to 37.04℃ ± 0.48℃ (+0.597℃, P < 0.0001). No side effects were experienced during the therapy. Moreover, most patients had an improvement in their symptoms and the ability to perform activities of daily living. Conclusion: Thermal therapy using hot water bottles is very safe and tends to reduce plasma BNP levels in hemodialysis patients with CHF.展开更多
目的研讨Hs-cTnT、BNP水平与ACS患者住院转归的相关性。方法选取曲靖市第一人民医院2022年1月-2022年12月收住的ACS患者1185例作为研究组,选取同期收住的1000名非器质性心脏病患者作为对照组。采集患者基线资料和临床转归情况,对比2组...目的研讨Hs-cTnT、BNP水平与ACS患者住院转归的相关性。方法选取曲靖市第一人民医院2022年1月-2022年12月收住的ACS患者1185例作为研究组,选取同期收住的1000名非器质性心脏病患者作为对照组。采集患者基线资料和临床转归情况,对比2组患者血清Hs-cTnT、BNP测值的差异。结果研究组Hs-cTnT、BNP测值均高于对照组(0.07±0.01 VS 51.12±3.21,P<0.05);研究组中不稳定心绞痛、ST段抬高心梗、非ST段抬高心梗三个亚组间临床不良转归与血清BNP测值存在相关性(1%VS 1%VS 1%,P<0.05)。Hs-cTnT测值在ST段抬高心肌梗死与非ST段抬高心肌梗死预后理想与预后不理想亚组间存在相关性(0.023 VS 0.009,P<0.05);而不稳定心绞痛预后理想与预后不理想组间血清Hs-cTnT测值无显著性差异(0.062,P>0.05)。结论血清Hs-cTnT、BNP对ACS患者的疾病严重程度、预后转归具有良好的预测价值,两者联合应用价值更高,血清BNP测值的转归预测价值更高。展开更多
目的:观察益气通络化痰方联合达格列净治疗急性心肌梗死后心力衰竭的疗效及对心功能、血清脑钠肽(BNP)、心肌肌钙蛋白l(cTnl)水平的影响,以期为临床治疗提供可靠参考。方法:按照纳入和排除标准选用因急性心肌梗死入院时或住院期间出现...目的:观察益气通络化痰方联合达格列净治疗急性心肌梗死后心力衰竭的疗效及对心功能、血清脑钠肽(BNP)、心肌肌钙蛋白l(cTnl)水平的影响,以期为临床治疗提供可靠参考。方法:按照纳入和排除标准选用因急性心肌梗死入院时或住院期间出现心力衰竭的104例患者为研究对象,采集时间为2022年9月~2023年9月,按照随机数字表法将上述患者随机分为两组,即实验组与对照组,每组52例,其中对照组患者标准心力衰竭治疗(达格列净),实验组在标准治疗上加用益气通络化痰方。比较2组疗效,对其中医证候积分、心功能指标[心排出量(CO)、左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]、血清指标[心房钠尿肽(ANP)、BNP、cTnl]的变化,并记录两组用药安全性及预后情况。结果:实验组总有效率为96.15%,而对照组总有效率为82.69%,两组相比差异有统计学意义( P <0.05);治疗后两组中医证候各项积分均较治疗前有不同程度的升高或降低( P <0.05),且治疗后相比,实验组LVESD、ANP、BNP、cTnl低于对照组( P <0.05),CO、LVEF、LVEDD高于对照组( P <0.05);实验组不良反应总发生率及因心衰再住院率分别为11.54%、5.77%,对照组分别为19.23%、19.23%,两组不良反应总发生率比较差异无统计学意义( P >0.05),但因心衰再住院率相比,差异有统计学意义( P <0.05)。结论:中医益气通络化痰方药联合达格列净用于急性心肌梗死后心力衰竭患者中疗效确切,不仅能有效恢复患者心功能作用,改善心室重构,还能调节ANP、BNP、cTnl等水平,抑制疾病进展,且预后良好,具有较大的临床应用价值。展开更多
文摘Aside from the important role of brain natriuretic peptide (BNP) in diagnosis, and differential diagnosis of heart failure, this biological peptide has proved to be an independent surrogate marker of rehospitalization and death of the fatal disease. Several randomized clinical trials demonstrated that drugs such as beta blocker, angiotensin converting enzyme inhibitor, spiro- nolactone and amiodarone have beneficial effects in decreasing circulating BNP level during the management of chronic heart failure. The optimization of clinical decision-making appeals for a representative surrogate marker for heart failure prognosis. The serial point-of-care assessments of BNP concentration provide a therapeutic goal of clinical multi-therapy and an objective guid- ance for optimal treatment of heart failure. Nevertheless new questions and problems in this area remain to be clarified. On the basis of current research advances, this article gives an overview of BNP peptide and its property and role in the management of heart failure.
文摘Objectives To observe the efficacy and safety of recombinant human brain natriuretic peptide(rh-BNP) on patients with acute myocardial infarction complicating congestive heart failure.Methods 40 patients with acute myocardial infarction complicated by congestive heart failure were randomly divided into control group and treatment group of 20 cases.The control group,15 cases of acute anterior myocardial infarction,5 cases of acute inferior wall myocardial infarction, 15 males and 5 females,aged 55-70 years,mean age 58±12 years;treated 16 cases of acute anterior myocardial infarction,4 cases of acute myocardial infarction,16 males and 4 females,aged 56-70 years,mean age 59±11 years;two groups of age,gender,severity of disease and vascular lesions no significant difference and comparable(P】0.05).Conventional group were given aspirin,clopidogrel, statins,Inotropic,diuretic and vasodilator therapy.In the con- ventional treatment group based on the use of recombinant human brain natriuretic peptide(new bios,Tibet Pharmaceutical Co.,Ltd.Chengdu Nuodikang biopharmaceutical production, usage:1.5μg/Kg intravenous injection(impact), then 0.0075μg-0.01μg/(kg·min)infusion rate).Continuous medication 72 h.The clinical symptoms observed for 3 days in patients before treatment and after treatment,heart rate,blood pressure and left ventricular ejection fraction (LVEF) and tumor necrosis factor(TNF-α),brain natriuretic peptide(BNP) levels were measured.Results In control group,8 cases markedly effect,5 cases effect and 7 cases no effect,the total effective rate was 65%;In treatment group,13 cases markedly effect,6 cases effect and 1 cases no effect,the total effective rate was 95%,compared with two groups P New bios treatment group significantly increased cardiac index(CI) in patients with heart failure and left ventricular ejection fraction(LVEF) than the control group(all P【0.05),further reduce the levels of tumor necrosis (TNF-α) and brain natriuretic peptide(BNP).Conclusions rh-BNP can improve symptoms and heart function,reduced plasma tumor necrosis factor(TNF-α) and BNP levels of acute myocardial infarction patients with congestive heart failure,the treatment safe and reliable.As small sample size observed,larger sample to be accumulated to further evaluate its efficacy and safety.
文摘Introduction: The use of repeated thermal therapy for improving the symptoms of chronic heart failure (CHF) has been recently demonstrated. Usually, thermal therapy requires an infrared dry sauna. However, it is difficult for small clinics to acquire such an expensive and extensive system. The author assessed the efficacy of its substitution with hot water bottles. Moreover, there are no prior studies demonstrating the efficacy of thermal therapy in hemodialysis patients with chronic heart failure. Methods: The author evaluated plasma brain natriuretic peptide (BNP) levels in 98 hemodialysis patients in a clinic. A total of nine patients whose BNP levels were more than 500 pg/mL agreed to be enrolled in this study and received thermal therapy using hot water bottles. Results: Plasma BNP levels, a potential marker for CHF, tended to decrease (891 ± 448 pg/mL to 680 ± 339 pg/mL), but the difference was not significant (P = 0.0845). The oral temperature changed from 36.44℃± 0.45℃ to 37.04℃ ± 0.48℃ (+0.597℃, P < 0.0001). No side effects were experienced during the therapy. Moreover, most patients had an improvement in their symptoms and the ability to perform activities of daily living. Conclusion: Thermal therapy using hot water bottles is very safe and tends to reduce plasma BNP levels in hemodialysis patients with CHF.
文摘目的研讨Hs-cTnT、BNP水平与ACS患者住院转归的相关性。方法选取曲靖市第一人民医院2022年1月-2022年12月收住的ACS患者1185例作为研究组,选取同期收住的1000名非器质性心脏病患者作为对照组。采集患者基线资料和临床转归情况,对比2组患者血清Hs-cTnT、BNP测值的差异。结果研究组Hs-cTnT、BNP测值均高于对照组(0.07±0.01 VS 51.12±3.21,P<0.05);研究组中不稳定心绞痛、ST段抬高心梗、非ST段抬高心梗三个亚组间临床不良转归与血清BNP测值存在相关性(1%VS 1%VS 1%,P<0.05)。Hs-cTnT测值在ST段抬高心肌梗死与非ST段抬高心肌梗死预后理想与预后不理想亚组间存在相关性(0.023 VS 0.009,P<0.05);而不稳定心绞痛预后理想与预后不理想组间血清Hs-cTnT测值无显著性差异(0.062,P>0.05)。结论血清Hs-cTnT、BNP对ACS患者的疾病严重程度、预后转归具有良好的预测价值,两者联合应用价值更高,血清BNP测值的转归预测价值更高。
文摘目的:观察益气通络化痰方联合达格列净治疗急性心肌梗死后心力衰竭的疗效及对心功能、血清脑钠肽(BNP)、心肌肌钙蛋白l(cTnl)水平的影响,以期为临床治疗提供可靠参考。方法:按照纳入和排除标准选用因急性心肌梗死入院时或住院期间出现心力衰竭的104例患者为研究对象,采集时间为2022年9月~2023年9月,按照随机数字表法将上述患者随机分为两组,即实验组与对照组,每组52例,其中对照组患者标准心力衰竭治疗(达格列净),实验组在标准治疗上加用益气通络化痰方。比较2组疗效,对其中医证候积分、心功能指标[心排出量(CO)、左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]、血清指标[心房钠尿肽(ANP)、BNP、cTnl]的变化,并记录两组用药安全性及预后情况。结果:实验组总有效率为96.15%,而对照组总有效率为82.69%,两组相比差异有统计学意义( P <0.05);治疗后两组中医证候各项积分均较治疗前有不同程度的升高或降低( P <0.05),且治疗后相比,实验组LVESD、ANP、BNP、cTnl低于对照组( P <0.05),CO、LVEF、LVEDD高于对照组( P <0.05);实验组不良反应总发生率及因心衰再住院率分别为11.54%、5.77%,对照组分别为19.23%、19.23%,两组不良反应总发生率比较差异无统计学意义( P >0.05),但因心衰再住院率相比,差异有统计学意义( P <0.05)。结论:中医益气通络化痰方药联合达格列净用于急性心肌梗死后心力衰竭患者中疗效确切,不仅能有效恢复患者心功能作用,改善心室重构,还能调节ANP、BNP、cTnl等水平,抑制疾病进展,且预后良好,具有较大的临床应用价值。
